# Lakefront Biotherapeutics NV: overview LKFT · Nasdaq · CIK 1421876 · [Healthcare](/sectors/healthcare.md) Pages: [Overview](/companies/lkft.md) · [Financials](/companies/lkft/financials.md) · [Filings](/companies/lkft/filings.md) · [Insiders](/companies/lkft/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [234](/filings/0001558370-24-004242.md) | [241](/filings/0001558370-25-003806.md) | [240](/filings/0001104659-26-035163.md) | [276](/filings/0001104659-26-035163.md) | [1,112](/filings/0001104659-26-035163.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(73.2%)](/filings/0001558370-24-004242.md) | [(54.3%)](/filings/0001558370-25-003806.md) | [(36.8%)](/filings/0001104659-26-035163.md) | [(68.3%)](/filings/0001104659-26-035163.md) | [26.5%](/filings/0001104659-26-035163.md) | | Net margin | % | [(44.0%)](/filings/0001558370-24-004242.md) | [(90.4%)](/filings/0001558370-25-003806.md) | [88.3%](/filings/0001104659-26-035163.md) | [26.9%](/filings/0001104659-26-035163.md) | [28.9%](/filings/0001104659-26-035163.md) | | Diluted EPS | $ per share | [(1.58)](/filings/0001558370-24-004242.md) | [(3.32)](/filings/0001558370-25-003806.md) | [3.21](/filings/0001104659-26-035163.md) | [1.12](/filings/0001104659-26-035163.md) | [4.87](/filings/0001104659-26-035163.md) | | Free cash flow | $m | [(558)](/filings/0001558370-24-004242.md) | [(528)](/filings/0001558370-25-003806.md) | [(425)](/filings/0001104659-26-035163.md) | [(337)](/filings/0001104659-26-035163.md) | [(271)](/filings/0001104659-26-035163.md) | - Revenue. XBRL Revenue: ifrs-full:Revenue. - Gross margin (gross profit / revenue). XBRL Revenue: ifrs-full:Revenue. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:Revenue. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLossAttributableToOwnersOfParent; Revenue: ifrs-full:Revenue. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/lkft/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [GILEAD SCIENCES, INC.](/funds/882095.md) | 2026-06-30 | $500.2m | 16,707,477 | | Unchanged | | [TANG CAPITAL MANAGEMENT LLC](/funds/1232621.md) | 2026-06-30 | $113.5m | 3,785,991 | | Unchanged | | [Madison Avenue Partners, LP](/funds/1801265.md) | 2026-06-30 | $103.4m | 3,447,807 | | Added +982,628 | | [Prosight Management, LP](/funds/1617201.md) | 2026-06-30 | $61.3m | 2,043,344 | | Added +493,344 | | [EcoR1 Capital, LLC](/funds/1587114.md) | 2026-06-30 | $50.0m | 1,667,119 | | Unchanged | | [AMERIPRISE FINANCIAL INC](/funds/820027.md) | 2026-06-30 | $38.1m | 1,272,249 | | Reduced −152,425 | | [DME Capital Management, LP](/funds/1489933.md) | 2026-06-30 | $14.5m | 482,746 | | Unchanged | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $13.5m | 449,100 | Put | Reduced −200 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $12.2m | 407,800 | | Added +92,400 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $10.1m | 338,152 | | Added +26,046 | ## Recent filings [All 528 filings](/companies/lkft/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-20 | 20:36 ET | [6-K](/filings/0001171843-26-006723.md) | Report of a foreign private issuer, period 2026-10-20 | 0001171843-26-006723 | | 2026-10-15 | 22:26 ET | [6-K](/filings/0001171843-26-006634.md) | Report of a foreign private issuer, period 2026-10-14 | 0001171843-26-006634 | | 2026-10-13 | 20:36 ET | [6-K](/filings/0001171843-26-006602.md) | Report of a foreign private issuer, period 2026-10-13 | 0001171843-26-006602 | | 2026-10-09 | 21:26 ET | [6-K](/filings/0001171843-26-006564.md) | Report of a foreign private issuer, period 2026-10-08 | 0001171843-26-006564 | | 2026-10-06 | 20:55 ET | [6-K](/filings/0001171843-26-006469.md) | Report of a foreign private issuer, period 2026-10-06 | 0001171843-26-006469 | | 2026-09-29 | 20:39 ET | [6-K](/filings/0001171843-26-006292.md) | Report of a foreign private issuer, period 2026-09-29 | 0001171843-26-006292 | | 2026-09-23 | 23:06 ET | [6-K](/filings/0001171843-26-006176.md) | Report of a foreign private issuer, period 2026-09-22 | 0001171843-26-006176 | | 2026-09-15 | 20:27 ET | [6-K](/filings/0001171843-26-006055.md) | Report of a foreign private issuer, period 2026-09-15 | 0001171843-26-006055 | | 2026-09-08 | 21:24 ET | [6-K](/filings/0001171843-26-005923.md) | Report of a foreign private issuer, period 2026-09-08 | 0001171843-26-005923 | | 2026-09-08 | 20:44 ET | [6-K](/filings/0001171843-26-005922.md) | Report of a foreign private issuer, period 2026-09-08 | 0001171843-26-005922 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-035163.md), filed Mar 26, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1421876 - Tickers: LKFT, GLPGF - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: C9 - Filer category: Large accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.